The optimal management of esophageal cancer patient is a matter of debate. There is very little data available on the benefit of chemotherapy in esophageal cancer patients with residual disease after trimodality therapy. The present article is a synopsis of the original article published in a renowned American Journal of Clinical Oncology. There are some studies that suggest the degree of pathologic response after neoadjuvant therapy is predictive of survival.
Specifically, residual disease achieved a worse survival compared with patients who had a complete pathologic response. However, It could be hypothesize that a postoperative chemotherapy in such patients may improve the outcomes. Hence, the present study was undertaken to evaluate the benefits of postoperative chemotherapy in patients with residual disease following a trimodality treatment or surgery. Materials and Methods:…
